These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23671038)

  • 21. Preparation and biodistribution in mice of [11C]carfentanil: a radiopharmaceutical for studying brain mu-opioid receptors by positron emission tomography.
    Saji H; Tsutsumi D; Magata Y; Iida Y; Konishi J; Yokoyama A
    Ann Nucl Med; 1992 Feb; 6(1):63-7. PubMed ID: 1325823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positron emission tomography measures of endogenous opioid neurotransmission and impulsiveness traits in humans.
    Love TM; Stohler CS; Zubieta JK
    Arch Gen Psychiatry; 2009 Oct; 66(10):1124-34. PubMed ID: 19805703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pain activation of human supraspinal opioid pathways as demonstrated by [11C]-carfentanil and positron emission tomography (PET).
    Bencherif B; Fuchs PN; Sheth R; Dannals RF; Campbell JN; Frost JJ
    Pain; 2002 Oct; 99(3):589-598. PubMed ID: 12406535
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adult attachment style is associated with cerebral μ-opioid receptor availability in humans.
    Nummenmaa L; Manninen S; Tuominen L; Hirvonen J; Kalliokoski KK; Nuutila P; Jääskeläinen IP; Hari R; Dunbar RI; Sams M
    Hum Brain Mapp; 2015 Sep; 36(9):3621-8. PubMed ID: 26046928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Quantification of 11C-MADAM binding to the serotonin transporter in the human brain.
    Lundberg J; Odano I; Olsson H; Halldin C; Farde L
    J Nucl Med; 2005 Sep; 46(9):1505-15. PubMed ID: 16157534
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Reduced mu opioid receptor availability in schizophrenia revealed with [
    Ashok AH; Myers J; Reis Marques T; Rabiner EA; Howes OD
    Nat Commun; 2019 Oct; 10(1):4493. PubMed ID: 31582737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mu-opioid receptor binding measured by [11C]carfentanil positron emission tomography is related to craving and mood in alcohol dependence.
    Bencherif B; Wand GS; McCaul ME; Kim YK; Ilgin N; Dannals RF; Frost JJ
    Biol Psychiatry; 2004 Feb; 55(3):255-62. PubMed ID: 14744466
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of chronic migraine attacks and their severity on the endogenous μ-opioid neurotransmission in the limbic system.
    Jassar H; Nascimento TD; Kaciroti N; DosSantos MF; Danciu T; Koeppe RA; Smith YR; Bigal ME; Porreca F; Casey KL; Zubieta JK; DaSilva AF
    Neuroimage Clin; 2019; 23():101905. PubMed ID: 31279240
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Binge eating disorder and morbid obesity are associated with lowered mu-opioid receptor availability in the brain.
    Joutsa J; Karlsson HK; Majuri J; Nuutila P; Helin S; Kaasinen V; Nummenmaa L
    Psychiatry Res Neuroimaging; 2018 Jun; 276():41-45. PubMed ID: 29655552
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Positron emission tomography imaging of mu- and delta-opioid receptor binding in alcohol-dependent and healthy control subjects.
    Weerts EM; Wand GS; Kuwabara H; Munro CA; Dannals RF; Hilton J; Frost JJ; McCaul ME
    Alcohol Clin Exp Res; 2011 Dec; 35(12):2162-73. PubMed ID: 21689118
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nicotine-specific and non-specific effects of cigarette smoking on endogenous opioid mechanisms.
    Nuechterlein EB; Ni L; Domino EF; Zubieta JK
    Prog Neuropsychopharmacol Biol Psychiatry; 2016 Aug; 69():69-77. PubMed ID: 27095017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Serotonin transporter density in binge eating disorder and pathological gambling: A PET study with [
    Majuri J; Joutsa J; Johansson J; Voon V; Parkkola R; Alho H; Arponen E; Kaasinen V
    Eur Neuropsychopharmacol; 2017 Dec; 27(12):1281-1288. PubMed ID: 29032922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serotonergic neurotransmission in the living human brain: a positron emission tomography study using [¹¹C]dasb and [¹¹C]WAY100635 in young healthy men.
    Takano H; Ito H; Takahashi H; Arakawa R; Okumura M; Kodaka F; Otsuka T; Kato M; Suhara T
    Synapse; 2011 Jul; 65(7):624-33. PubMed ID: 21484882
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placebo effects on human mu-opioid activity during pain.
    Wager TD; Scott DJ; Zubieta JK
    Proc Natl Acad Sci U S A; 2007 Jun; 104(26):11056-61. PubMed ID: 17578917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses.
    Scott DJ; Stohler CS; Egnatuk CM; Wang H; Koeppe RA; Zubieta JK
    Arch Gen Psychiatry; 2008 Feb; 65(2):220-31. PubMed ID: 18250260
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Quantification of brain mu-opioid receptors with [11C]carfentanil: reference-tissue methods.
    Endres CJ; Bencherif B; Hilton J; Madar I; Frost JJ
    Nucl Med Biol; 2003 Feb; 30(2):177-86. PubMed ID: 12623117
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Striatal μ-opioid receptor availability predicts cold pressor pain threshold in healthy human subjects.
    Hagelberg N; Aalto S; Tuominen L; Pesonen U; Någren K; Hietala J; Scheinin H; Pertovaara A; Martikainen IK
    Neurosci Lett; 2012 Jul; 521(1):11-4. PubMed ID: 22622175
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant mesolimbic dopamine-opiate interaction in obesity.
    Tuominen L; Tuulari J; Karlsson H; Hirvonen J; Helin S; Salminen P; Parkkola R; Hietala J; Nuutila P; Nummenmaa L
    Neuroimage; 2015 Nov; 122():80-6. PubMed ID: 26260431
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Behavioural activation system sensitivity is associated with cerebral μ-opioid receptor availability.
    Karjalainen T; Tuominen L; Manninen S; Kalliokoski KK; Nuutila P; Jääskeläinen IP; Hari R; Sams M; Nummenmaa L
    Soc Cogn Affect Neurosci; 2016 Aug; 11(8):1310-6. PubMed ID: 27053768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neurotransmitters behind pain relief with transcranial magnetic stimulation - positron emission tomography evidence for release of endogenous opioids.
    Lamusuo S; Hirvonen J; Lindholm P; Martikainen IK; Hagelberg N; Parkkola R; Taiminen T; Hietala J; Helin S; Virtanen A; Pertovaara A; Jääskeläinen SK
    Eur J Pain; 2017 Oct; 21(9):1505-1515. PubMed ID: 28493519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.